Genmab — August 2019

[Bulder]

Bergenbio's treatment is a combo. EnaV is mono and has not yet been tested in combination. Still too early to say. Maybe a comment from Sukker on this issue?

[GeorgeBest]

BerginBio is second line. EnaV is 4th plus lines. Therefore the EnaV patients are much more sick.

[Bulder]

Thx GB. I was not sure about that. Where did you find that info?

[GeorgeBest]

Bulder: can you read Nordea comments from 22 August?

[Solsen]

In the announcement they mentioned 4 lines or less

[GeorgeBest]

Nordea write: patients had failed 4 or more prior lines of therapy including platinum based chemo

[Solsen]

Makes a difference - perhaps Iam wrong

[GeorgeBest]

So infact EnaV is 5th line...

[Solsen]

who had failed ≤4 prior lines of therapy - right

[Solsen]

https://wclc2019.iaslc.org/wp-content/uploads/2019/08/WCLC2019-Abstract-Book_web-friendly.pdf pp 217-218

[Solsen]

Difficult comparison to Bergenbios compound.

[Bulder]

patients with stage III/IV
NSCLC without sensitizing EGFR mutations (EGFR WT) or ALK
rearrangements (ALK-
) who had failed ≤4 prior lines of therapy, så nogle har haft færre end 4 behandlinger.

[Bulder]

Bergenbio: Cohort A will consist of patients who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind. Cohort B will consist of patients with a maximum of 2 prior lines whereas the most recent line must have included a PD-(L)1 inhibitor.

[nohope]

Er det egentlig ikke et lidt underligt kriterium ? Mindre end 4 - så kan det være 0-1-2-3-4 ? Det ville være mere logisk hvis det hed 4 eller flere ?

[Bulder]

Det betyder op til og med 4. linje.

[Bulder]

... eller ned om man vil

[nohope]

Det er jeg med på, men synes stadig det er underligt kriterium.

[nohope]

Når du eksperimenterer så plejer du at få dem der opgivet?

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

Svært at sammenligne Genmabs ADC med BergenBios bemcentinib - et underligt dilemma er også, at patienter skal være godt syge for at udtrykke AXL. Tænker umiddelbart at Bemcentinib og EnaV vil sigte efter forskellige patientgrupper